問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Gastroenterological Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital
National Health Research Institutes

Division of Hematology & Oncology

更新時間：2023-09-19

沈延盛Shan, Yan-Shen
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • ncku013@hotmail.com

Recruiting Trial

57Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈延盛

List

114Cases

2025-11-01 - 2031-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2020-06-26 - 2026-12-31

Phase I/II

Active
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)

  • Condition/Disease

    HER2 overexpressing locally advanced or metastatic, unresectable Gastric Cancer.

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2027-12-31

Phase II

Active
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.

  • Condition/Disease

    Gastric Cancer Gastroesophageal Junction Cancer Pancreatic Adenocarcinoma

  • Test Drug

    AZD0901

Participate Sites
5Sites

Recruiting4Sites

2018-12-13 - 2024-08-27

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2020-01-01 - 2024-12-25

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-12-06 - 2025-12-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors

  • Test Drug

    CVM-1118

Participate Sites
8Sites

Recruiting4Sites

Terminated3Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2024-07-01 - 2029-12-31

Phase I/II

Active
A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined With Chemotherapy in Patients With PDA or Cholangiocarcinoma After Surgery

  • Condition/Disease

    Pancreatic Carcinoma Stage II、Cholangiocarcinoma Resectable

  • Test Drug

    溶液劑

Participate Sites
1Sites

Recruiting1Sites

2024-03-01 - 2026-12-31

Phase I

Active
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LBL-01 Injection in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injective

Participate Sites
3Sites

Recruiting3Sites

2018-02-14 - 2022-12-31

Phase I/II

Completed
A Phase I/II study to determine the maximum tolerated dose (MTD) and to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of antroquinonol in combination with nab-paclitaxel and gemcitabine in first line metastatic pancreatic cancer.

  • Condition/Disease

    Pancreatic Neoplasm

  • Test Drug

    Hocena

Participate Sites
2Sites

Recruiting2Sites

李重賓
Taipei Veterans General Hospital

Division of Hematology & Oncology

沈延盛
National Taiwan University Hospital

Division of General Surgery

2020-11-13 - 2026-12-31

Phase I

Active
A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

  • Condition/Disease

    Pancreatic Cancer

  • Test Drug

    凍晶注射劑

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB